Pfizer, a pharmaceutical company, said Thursday that its coronavirus vaccine is losing effectiveness and that it is ramping up attempts to find a booster dose that can protect individuals from variations. After publishing new data on how effectively a third dosage of vaccine works, it said it would seek emergency use authorisation from the US Food and Drug Administration for a booster dose in August.
However, in an uncommon move, two major federal agencies stated that Americans do not require boosters at this time and that it is not up to companies to choose when they are required. The FDA and the Centers for Disease Control and Prevention made a joint statement hours following Pfizer statement, claiming that Americans do not require booster shots yet.
In addition, the Delta version is becoming the dominant variant in Israel and many other countries throughout this time. These findings are in line with the results of the Companies’ ongoing Phase 3 trial. While protection against severe disease remained strong for the entire six months, efficacy against symptomatic disease is predicted to wane with time, with variations continuing to arise.
Pfizer and BioNTech feel that a third dose may be useful within 6 to 12 months after the second dose to maintain the maximum levels of protection, based on the totality of the data they have to date. Fully vaccinated people have a low chance of infection, even from the Delta or B.1.617.2 variation, which is more transmissible than earlier lineages of the virus, according to US health officials.